Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy

<h4>Background</h4> Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite ou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luis E. Echeverría, Lyda Z. Rojas, Sergio Alejandro Gómez-Ochoa, Oscar L. Rueda-Ochoa, Cristian David Sosa-Vesga, Taulant Muka, James L. Januzzi, Rachel Marcus, Carlos A. Morillo
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/207dd94dfad54534b5ae8267eb115b65
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:207dd94dfad54534b5ae8267eb115b65
record_format	dspace
spelling	oai:doaj.org-article:207dd94dfad54534b5ae8267eb115b652021-11-04T06:49:37ZCardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy1932-6203https://doaj.org/article/207dd94dfad54534b5ae8267eb115b652021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553084/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite outcome (CO), including the need for heart transplantation, use of left ventricular assist devices, and mortality. <h4>Methods</h4> Prospective cohort study of 100 adults with different stages of CCM. Serum concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble (sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using Cox proportional hazard models. <h4>Results</h4> During a median follow-up of 52 months, the mortality rate was 20%, while the CO was observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31–7.79). No events were reported in the patients in whom the two biomarkers were under the cut-off values, and when both levels were above cut-off values, the CO was observed in 60.71%. <h4>Conclusion</h4> The combination of NT-proBNP and hs-TnT above their selected cut-off values is associated with a 3-fold increase in the risk of the composite outcome among CCM patients. The use of cardiac biomarkers may improve prognostic evaluation of patients with CCM.Luis E. EcheverríaLyda Z. RojasSergio Alejandro Gómez-OchoaOscar L. Rueda-OchoaCristian David Sosa-VesgaTaulant MukaJames L. JanuzziRachel MarcusCarlos A. MorilloPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Luis E. Echeverría Lyda Z. Rojas Sergio Alejandro Gómez-Ochoa Oscar L. Rueda-Ochoa Cristian David Sosa-Vesga Taulant Muka James L. Januzzi Rachel Marcus Carlos A. Morillo Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
description	<h4>Background</h4> Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite outcome (CO), including the need for heart transplantation, use of left ventricular assist devices, and mortality. <h4>Methods</h4> Prospective cohort study of 100 adults with different stages of CCM. Serum concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble (sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using Cox proportional hazard models. <h4>Results</h4> During a median follow-up of 52 months, the mortality rate was 20%, while the CO was observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31–7.79). No events were reported in the patients in whom the two biomarkers were under the cut-off values, and when both levels were above cut-off values, the CO was observed in 60.71%. <h4>Conclusion</h4> The combination of NT-proBNP and hs-TnT above their selected cut-off values is associated with a 3-fold increase in the risk of the composite outcome among CCM patients. The use of cardiac biomarkers may improve prognostic evaluation of patients with CCM.
format	article
author	Luis E. Echeverría Lyda Z. Rojas Sergio Alejandro Gómez-Ochoa Oscar L. Rueda-Ochoa Cristian David Sosa-Vesga Taulant Muka James L. Januzzi Rachel Marcus Carlos A. Morillo
author_facet	Luis E. Echeverría Lyda Z. Rojas Sergio Alejandro Gómez-Ochoa Oscar L. Rueda-Ochoa Cristian David Sosa-Vesga Taulant Muka James L. Januzzi Rachel Marcus Carlos A. Morillo
author_sort	Luis E. Echeverría
title	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
title_short	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
title_full	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
title_fullStr	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
title_full_unstemmed	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy
title_sort	cardiovascular biomarkers as predictors of adverse outcomes in chronic chagas cardiomyopathy
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/207dd94dfad54534b5ae8267eb115b65
work_keys_str_mv	AT luiseecheverria cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT lydazrojas cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT sergioalejandrogomezochoa cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT oscarlruedaochoa cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT cristiandavidsosavesga cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT taulantmuka cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT jamesljanuzzi cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT rachelmarcus cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy AT carlosamorillo cardiovascularbiomarkersaspredictorsofadverseoutcomesinchronicchagascardiomyopathy
_version_	1718445071364259840

Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy

Ejemplares similares